Local SARS-CoV-2 Peptide-Specific Immune Responses in Lungs of Convalescent and Uninfected Human Subjects

Kayla F. Goliwas[1], Anthony M. Wood[1], Christopher S. Simmons[1], Rabisa Khan[1], Saad A. Khan[1], Yong Wang[1], Joel L. Berry[2], Mohammad Athar[3], James A. Mobley[4], Young-il Kim[5], Victor J. Thannickal[6], Kevin S. Harrod[4], James M. Donahue[7] and Jessy S. Deshane[1*].

[1] Department of Medicine
  Division of Pulmonary, Allergy, and Critical Care Medicine
  University of Alabama at Birmingham
  Birmingham, AL

[2] Department of Biomedical Engineering
  University of Alabama at Birmingham
  Birmingham, AL

[3] Department of Dermatology
  University of Alabama at Birmingham
  Birmingham, AL

[4] Department of Anesthesiology and Perioperative Medicine
  University of Alabama at Birmingham
  Birmingham, AL

[5] Department of Medicine, Division of Preventative Medicine
  University of Alabama at Birmingham
  Birmingham, AL

[6] John W. Deming Department of Medicine,
  Tulane University School of Medicine

[7] Department of Surgery
  University of Alabama at Birmingham
  Birmingham, AL

* Corresponding author:
  Jessy S. Deshane
  Associate Professor
  Department of Medicine
  Division of Pulmonary Allergy and Critical Care Medicine
  THT 433A, 1900 University Boulevard
  University of Alabama at Birmingham
  Birmingham, AL 35294-0006
  (205) 996-2041
  jessydeshane@uabmc.edu

SUMMARY

Multi-specific and long-lasting T cell immunity have been recognized as indicators for long term protection against pathogens including the novel coronavirus SARS-CoV-2, the causative agent of the COVID-19 pandemic. Functional significance of peripheral memory T cells in individuals recovering from COVID-19 (COVID-19[+]) are beginning to be appreciated; but little is known about lung resident memory T cells (lung TRM) in SARS-CoV-2 infection. Here, we utilize a perfused three dimensional (3D) human lung tissue model and identify pre-existing local T cell immunity against SARS-CoV-2 proteins in lung tissues. We report *ex vivo* maintenance of functional multi-specific IFN-γ secreting lung TRM in COVID-19[+] and their induction in lung tissues of vaccinated COVID-19[+]. Importantly, we identify SARS-CoV-2 peptide-responding B cells and IgA[+] plasma cells in lung tissues of COVID-19[+] in *ex vivo* 3D-tissue models. Our study highlights the importance of balanced and local anti-viral immune response in the lung with persistent induction of TRM and IgA[+] plasma cells for future protection against SARS-CoV-2 infection. Further, our data suggest that inclusion of multiple viral antigens in vaccine approaches may broaden the functional profile of memory T cells to combat the severity of coronavirus infection.

INTRODUCTION

COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, is a global health concern [1-3]. Infected individuals develop lymphopenia and demonstrate hyperactivated and exhausted T cell responses that contribute to prolonged immune dysregulation, a hallmark of SARS-CoV-2 infection[4-8]. Although vaccine efforts have been successful, the emergence of variants[9,10], persistence of infection and vaccine hesitancy continue to pose problems for eradication and management of COVID-19. All approved COVID-19 vaccines, thus far, utilize intramuscular delivery of SARS-CoV-2 spike mRNA or inactivated virus to elicit humoral immunity, a strategy that has not offered long-term protection.

Evidence from previous zoonotic coronaviruses indicates that an important determinant for recovery and long-term protection is coronavirus-specific T cell immunity[11-13]. During the initial phase of the pandemic, 20-50% unexposed individuals showed T cell reactivity to SARS-CoV-2 antigen peptide pools[6,7,14-17]. Pre-existing CD4 and CD8 T cell responses against both structural (nucleocapsid, N) and non-structural regions of SARS-CoV-2 were noted in peripheral blood mononuclear cells of COVID-19 convalescent individuals[6,7,14-23]. In the majority of COVID-19 recovering individuals (COVID-19$^+$), larger overall SARS-CoV-2-specific CD4 and CD8 T cell responses were seen with severe disease[18,22,23]. However, an increase in polyfunctional CD8$^+$ T cells were noted in mild cases[18,22,23]. Furthermore, long-lasting memory T cells displayed robust cross-reactivity to N protein of SARS-CoV and SARS-CoV-2[24,25]. Interestingly, SARS-CoV-2-specfic T cells are present in individuals with no prior history of SARS suggesting pre-existing cross-reactive immune memory to seasonal coronaviruses[7,17].

As memory T cell response induced by previous viral pathogens can shape susceptibility to subsequent viral infections including SARS-CoV-2, and/or influence clinical severity of COVID-19, pre-existing memory T cells that recognize SARS-CoV-2 have been implicated[22,24-29]. Upon SARS-CoV-2 exposure, a faster and stronger immune response is anticipated in

individuals with pre-existing T cell immunity[7]. Additionally, increased memory T follicular helper

CD4$^+$ T cells could facilitate a rapid SARS-CoV-2 neutralizing antibody response[30]. The increase

in memory CD4$^+$ and CD8$^+$ T cells may enable direct antiviral immunity in the lungs and

nasopharynx; pre-existing CD4$^+$ T cell memory could influence vaccination outcomes, leading to

a quicker robust immune response and development of neutralizing antibodies[31]. Alternatively,

pre-existing immunity could be detrimental due to exuberant antibody-mediated inflammation or

from inadequate immune responses[32]. Thus, accurate measurements of pre-existing T cell

immunity are essential to an understanding of disease severity and effective vaccine responses.

The assessment of a complete SARS-CoV-2 reactive T cell pool has been challenging; both the

breadth and depth of the SARS-CoV-2 specific T cell responses are not fully understood, as

circulating T cells may not represent lung-specific responses to viral infection and/or reflect

direct anti-viral immunity in the lungs or the nasopharynx.

In addition to T cell immunity, the most anticipated and monitored protective response is

the evolution of antibody immunity to SARS-CoV-2 [33]. While waning antibody levels have been

reported after SARS-CoV-2 infection [34-37], very few studies have evaluated the nature and

quality of the memory B cells[33] that would be required to produce antibodies upon reinfection.

Additionally, early SARS-CoV-2–specific humoral responses were dominated by IgA and not

IgG antibodies [38,39]; but their presence and function in the lungs of COVID-19$^+$ are largely

unknown.

We utilized a perfused three-dimensional lung tissue culture model that maintains the

tissue architecture of the human lung for the assessment of pre-existing T cell immunity in the

lung tissues of previously uninfected (UN) and COVID-19$^+$ individuals. Utilizing this model, we

demonstrate local immune responses to SARS-CoV-2 peptide pools in the lungs of UN

individuals induced by pre-existing T cell immunity and significant memory T cell response in the

lungs of COVID-19[+] individuals. Importantly, we identify, for the first time, significant IgA levels

and IgA-secreting plasma cells in COVID-19 infected lungs.

RESULTS

Ex Vivo **Perfusion of Human Lung Tissues**

Remnant surgical specimen from individuals (no history of SARS-CoV-2 infection)

undergoing lung resection surgeries were collected. For *ex vivo* culture, 5 mm diameter tissue

cores were generated and one tissue core was placed into the central chamber of a bioreactor

containing a mixture of extracellular matrix (ECM) components. The tissue/ECM support was

penetrated with five 400 micron Teflon coated stainless steel wires to generate through-

channels for adequate tissue perfusion. Wires were removed following ECM polymerization. A

serum-free, defined tissue culture media was then perfused from a media reservoir through the

tissue volume and collected in a collection reservoir using a peristaltic pump (**Figure 1A-B**).

Using this culture system, we observed maintenance of histologic tissue architecture (**Extended**

Fig. 1A), as well as cell density (cells/area, **Extended Fig. 1B**) over a two-week culture period.

Further, lactate dehydrogenase (LDH) remained unchanged during culture (**Extended Fig. 1C**),

indicating sustained viability. The ECM composition utilized here has been used with earlier

prototype bioreactors to generate viable cell culture models of lung and breast carcinoma

(Goliwas et. al. 2021; Goliwas et al, 2016). These platforms were adapted here for the *ex vivo*

culture of human lung tissues. Cell phenotyping showed maintenance of lung epithelial and

endothelial cells, as well as fibroblasts and lymphocytes including CD8[+] T cells (**Extended Figs.**

1D-H), and proteomic analyses showed maintenance of the lung ECM (**Extended Fig. 1I**).

Cellular Landscape and Response to SARS-CoV-2 Peptides within the Lung Tissues of

Previously Uninfected and Convalescent Individuals

Local immune responses to SARS-CoV-2 peptides were compared in lung tissue

specimen collected from eight individuals who were not previously infected with SARS-CoV-2

(uninfected, UN) and four convalescent individuals who previously tested positive for SARS-

CoV-2 and cleared the virus (COVID-19$^+$), **Extended Data Tables 1 and 2** with subject

demographics). Tissue cores were cultured *ex vivo* using the bioreactor platform and following

four to five days perfusion culture, peptide pools covering the SARS-CoV-2 membrane

glycoprotein (M peptide), nucleocapsid phosphoprotein (N peptide), or the immunodominant

sequence of the spike protein (S peptide) were added to circulating media and cellular response

was compared to vehicle control exposed tissues (**Figure 1C**).

While baseline phenotyping showed no difference in epithelial cell populations,

endothelial cells, CD45$^+$ immune cells, TNF-α$^+$ immune cells, or CD4$^+$ T cells within the lung

tissues of COVID-19$^+$ and UN individuals (**Extended Figs. 2A-C, Extended Figs. 3A-B,**

Extended Fig. 4A, Figure 2A-B), a significant increase in % PD-1$^+$ CD4$^+$ T cells was noted

(**Figure 2C**). Other subpopulations of CD4$^+$ T cells showed no difference at baseline within the

lungs of COVID-19$^+$ and UN individuals (**Figure 2D, Extended Figs. 5A-E**). The frequency of

CD8$^+$ T cells was moderately increased in COVID-19$^+$ compared to UN lung tissues (**Figure**

2E). Similar to CD4$^+$ T cells, the PD-1$^+$ CD8$^+$ T cells were elevated in COVID-19$^+$ at baseline

(**Figure 2F**), but no differences were observed in other subpopulations of CD8$^+$ T cells (**Figure**

2G, Extended Figs. 6A-E). The maintenance of cell populations over the culture period was

assessed, comparing UN or COVID-19$^+$ tissues in culture to the respective starting tissues.

While the overall CD45$^+$ frequencies declined over the culture period, the change in frequencies

of epithelial, endothelial, T or B cell populations comparing UN and COVID-19$^+$ lung tissues

were not significantly different (**Extended Figs. 2D, 3C, 4B, 7, 8L-Y, & 9K-Q**); naïve CD8$^+$ T

cells showed a trending difference (p=0.068) following *ex vivo* culture (**Extended Fig 8S**).

Following exposure to the SARS-CoV-2 peptide pools, the lung tissue cores were

collagenase digested and alterations in the cellular landscape and immune response were

evaluated. As noted at baseline, no differences were observed in the epithelial cell populations,

but an increase in CD31$^+$ endothelial cells was found with M peptide treatment in COVID-19$^+$

samples (**Extended Fig. 2E** & **Extended Fig. 3D**). No changes were noted in the CD45$^+$

immune cells, TNF-α$^+$ immune cells, or the CD4$^+$ T cells with peptide exposure within UN or

COVID-19$^+$ lung tissues (**Figures 2H-I, Extended Fig. 4C**). The change in frequency of the PD-

1$^+$ CD4$^+$ T cells between control and N peptide-exposed tissues was greater in COVID-19$^+$

compared to UN lung tissues (**Figure 2J**). Additionally, hyperactivated CD4$^+$ T cells showed an

increasing trend in COVID-19$^+$ tissues (p=0.075) exposed to the M peptide when compared to

control; this change was not observed in UN tissues (**Figure 2K**). No significant changes were

noted in proliferating, antigen specific, or IFN-γ$^+$CD4$^+$ T cells (**Extended Figs. 5F-I**). The

frequency of CD8$^+$ T cells increased in response to the M peptide (p=0.064) in UN tissues when

compared to control. This population also showed a significant increase when N peptide-

response was compared between UN and COVID-19$^+$, with increased CD8$^+$ T cells in COVID-

19$^+$ (**Figure 2L**). The frequency of proliferating and antigen specific CD8$^+$ T cells, although not

significant (*p* = 0.051 with M peptide exposure and *p* = 0.093 with S peptide exposure,

respectively), increased with peptide exposure in UN, but not in the COVID-19$^+$ tissues

(**Extended Figs. 6F-G**). No significant differences were observed in PD-1$^+$, hyperactivated, or

IFN-γ$^+$CD8$^+$ T cells (**Figures 2M-N, Extended Figs. 6H-I**).

Memory T cell Response to SARS-CoV-2 Peptides within the Lung Tissues of

Convalescent Individuals

We assessed T cell memory subsets within the lung tissues of UN and COVID-19$^+$

individuals, as they play a vital role in viral clearance during re-infection and recent studies

identified functional memory T cells within the peripheral blood of COVID-19$^+$ patients[22,24-29]. At

baseline, CD4$^+$ or CD8$^+$ lung memory T cell subsets were not significantly different comparing

UN and COVID-19$^+$ tissues (**Figure 3A-J**, **Extended Figs. 8A-G**). However, tissue resident

memory (TRM) and effector memory (EM) were the most prevalent subsets within the lung

tissue (**Figures 3A, 3F, 3E & 3J)**. Following *ex vivo* culture, TRM responses to all peptide pools

were noted within the UN tissues, with decreasing CD4$^+$ TRM frequency with peptide exposure

(**Figure 3K**). We determined the % IFN-γ^+ subsets within the CD4$^+$ and CD8$^+$ TRM as well as %

TRM within the overall IFN-γ^+ CD4$^+$ and CD8$^+$ cells. Although statistical significance was not

observed when comparing UN and COVID-19$^+$, patient-specific differences were noted in

COVID-19$^+$. At baseline, the average % IFN-γ^+ CD8$^+$TRM in COVID-19$^+$ was 1.71 fold higher

than UN average (**Figure 3G).** Within the COVID-19$^+$, % IFN-γ^+ CD8$^+$TRM and % IFN-γ^+

CD4$^+$TRM in Subject #10 who received COVID-19 vaccination, were 3.69 and 4.65 fold higher,

respectively, than average of UN (**Figure 3Q, 3L).** While meaningful fold change in average

%TRM within CD8$^+$IFN-γ^+ was not noted in this individual, the average %TRM within CD4$^+$IFN-γ^+

in COVID-19$^+$ was 2 fold higher than UN average (**Figure 3M).** Of the total IFN-γ^+ CD8$^+$ T cells

in the lungs of COVID-19$^+$ individuals #11 (COVID$^+$ twice) and #8, 40-50% were TRM (**Figure**

3R). Both % IFN-γ^+ of the CD8$^+$TRM (2.55-fold) and % TRM within CD4$^+$IFN-γ^+ (2.26-fold) were

higher in Subject #11 (**Figure 3R, 3L**). In COVID-19$^+$ Subject #10, the % IFN-γ^+ CD8$^+$TRM was

1.5 fold higher in response to the S peptide when compared to control (**Figure 3Q**), and the

%TRM within CD8$^+$IFN-γ^+ cells was 3.25 fold and 2.72 fold higher in M-peptide and N-peptide

exposed tissues, respectively (**Figure 3R**). Interestingly, in COVID-19$^+$ #5, % IFN-γ^+ CD8$^+$TRM

was 5.88 fold and 10 fold higher in the S-peptide and M-peptide treated samples compared to

the respective controls; robust response was not noted with N-peptide (**Figure 3Q**). The % TRM

CD4$^+$IFN-γ^+ in COVID-19$^+$ #5 was 12.5 fold higher in response to the S peptide when compared

to control, whereas other COVID-19$^+$ did not demonstrate a robust response in (**Figure 3M**); in

COVID-19$^+$ #8, the M-peptide response was 3.39 fold higher compared to control (**Figure 3M**).

The % IFN-γ^+ within the CD4$^+$TRM cells that respond to the S peptide were 14.3 fold higher

compared to control in COVID-19$^+$ #5, while this response was minimal in COVID-19$^+$ #10 and

11 (**Figure 3L**). But the % IFN-γ producing CD4$^+$TRM were 2.87 fold higher in response to the M

peptide and were 3.31 fold higher in response to the N peptide in vaccinated COVID-19$^+$ #10

and COVID-19$^+$ #11 (COVID$^+$ twice) respectively, compared to control (**Figure 3L**).

Additionally, stem cell like CD4$^+$ memory T cells increased (p=0.078) with M peptide

exposure (**Extended Fig. 8H**), whereas both naïve and central memory CD4$^+$ T cell frequencies

decreased with M-peptide exposure; a similar reduction in N peptide response within naïve

CD4$^+$ T cells was noted in UN tissues (**Figures 3N, Extended Fig. 8I**). Interestingly, the change

in the frequency of naïve CD4$^+$ T cells, when comparing the control and S peptide response,

was significantly increased in COVID-19$^+$ when compared to UN (**Figure 3N**). No significant

differences were observed in CD4$^+$ EM cells (**Figure 3O**). Amongst CD8$^+$ memory subsets, a

trend towards a reduction in S peptide- responding TRM CD8$^+$ T cells was noted (p=0.076),

when compared to respective controls in UN tissues. This trend coincided with an increasing

trend in the change in % TRM between control and S peptide exposure when comparing UN

and COVID-19$^+$; this cell population increased with peptide stimulation in COVID-19$^+$ tissues

(**Figure 3P**). No differences were observed in CD8$^+$ stem cell like memory T cells and minimal

changes were observed in CD8$^+$ naïve and central memory subsets (**Extended Fig. 8J-K,**

Figure 3S). Importantly, CD8$^+$ EM cells tended to increase with peptide exposure in COVID-19$^+$

tissues, with a significant increase in the change between control and S peptide treated samples

in COVID-19$^+$ compared to UN tissues (**Figure 3T**).

As the humoral immune response to infection is essential for protection and has not been

evaluated in SARS-CoV-2 convalescence at the tissue level, we evaluated B cell subsets in a

subset of the UN and COVID-19$^+$ lung tissues. No significant differences in B cell subsets were

noted at baseline (**Figure 4A-C, Extended Figs. 9A-F**). A trend towards an increase in CD19$^+$

B cells following *ex vivo* culture and S peptide exposure (p=0.068) was observed in COVID-19$^+$

tissues when compared to control. Furthermore, the change between control and S peptide

exposed samples was significantly different in COVID-19$^+$ when compared to UN tissues

(**Figure 4D**). When evaluating memory B cells, opposing changes between control and M

peptide exposed samples were noted in UN and COVID-19$^+$ (**Extended Fig. 9H**). While

transitional B cells were boosted in UN, plasmablasts tended to be higher in COVID-19$^+$

samples; all other B cell subsets remained unchanged with peptide exposure (**Figures 4E-F,**

Extended Figs. 9G and 9I-J). Evaluation of humoral responses in the lung tissue supernatants

showed that IgA levels were higher at baseline in 2/4 recovering COVID-19$^+$ (#11, infected twice

and unvaccinated) and # 8 (infected once and unvaccinated, see Extended Table 2) compared

to UN (**Figure 4G**). The IgA response was more dominant than the IgG response in these lung

tissue supernatants of COVID-19$^+$ (**Figure 4H**). Additionally, while the baseline IgA response

was not detectable in COVID-19$^+$ #5 (infected once and unvaccinated), both M and N peptide

stimulation increased IgA levels substantially **(Figure 4G).** Similarly, while baseline IgA was also

low in COVID-19$^+$ # 10 (vaccinated after first infection), both M and N peptide stimulation

increased IgA levels. We then used confocal microscopy to identify CD138$^+$ plasma cells

secreting IgA in the lungs of COVID-19$^+$ compared to UN. Consistent with SARS-CoV-2 specific

IgA levels, we detected more CD138$^+$IgA$^+$ cells in the lungs of COVID-19$^+$ individuals at

baseline and in response to SARS-CoV-2-specific peptides **(Figures 4I and Extended Fig. 10).**

CONCLUSIONS

T cell dynamics during both the acute and memory phases following SARS-CoV-2 infection

determine the specific T cell and humoral responses optimized for host protection. Specifically,

the role of SARS-CoV-2 specific effector T cells on viral clearance and their accumulation in

COVID-19$^+$ and recovered individuals over time requires further study; however, modeling local

immune responses against SARS-CoV-2 has posed challenges. We utilized a novel three-

dimensional perfused human lung tissue model that maintains cellular heterogeneity, viability

and extracellular matrix components over an extended culture period. In this model, we

evaluated local immune responses to SARS-CoV-2 peptide pools that represent membrane,

nucleocapsid and spike proteins of SARS-CoV-2. We provide evidence for pre-existing T cell

immunity and SARS-CoV-2 peptide-specific local T and B lymphocyte memory responses in

lung tissues from COVID-19[+] and uninfected (UN) individuals.

Evidence of elevated frequencies of PD-1[+] CD4[+] and/or CD8[+] T cells in our COVID-19[+]

lung tissue models are consistent with the reported increase of circulating PD-1[+] cells in COVID-

19[+] patients [40-43], suggesting that these models are relevant for evaluation of antigen primed

responses. Pre-existing T cell immunity in UN lungs, however, was represented by M-peptide

response in CD8[+] stem cell like memory cells, and not N-peptide responding CD8[+] T cells as

reported earlier in circulation [6,7,14-23]. Interestingly, the change in frequency of overall N-peptide

responding CD8[+] T cells was increased significantly in COVID-19[+] compared to UN.

Additionally, the change in N-peptide responding PD-1[+] CD4[+]T cells was significantly higher in

COVID-19[+] compared to UN. While these changes are not consistent with what is reported in

circulation, the differences in the lung niche may impact local immune responses differently from

what is seen in circulation.

Previous studies in SARS-CoV recovered individuals have identified persistent memory

T cells that suggested vaccine-mediated induction of TRMs may provide long-term protection

against this pandemic[12]. Consistent with this, a larger proportion of CD8[+]T cell EM cells and

those with TRM phenotype have been identified in bronchoalveolar lavage fluid and lung tissues

of individuals with COVID-19[44,45]. A key role for TRMs in protection against pathogen challenge

has been established for many tissues, including the lung[12,44-46]. We report here, the existence

and long-term maintenance in culture of a high frequency of SARS-CoV-2-S-peptide specific

EM CD8[+] T cells and TRM in COVID-19[+] lungs. In our studies, 3 out of the 4 COVID-19[+]

showed robust increase in % IFN-γ[+]TRM. While the vaccinated COVID-19[+] did not demonstrate

a significant increase compared to other COVID-19[+] at baseline, an IFN-γ[+] S-peptide response

in TRMs was noted in this tissue. Further, fold change in % TRM of the total IFN-γ[+] cells which

showed M and N-peptide responses were increased in the vaccinated COVID-19[+]. These

observations are consistent with vaccine mediated induction of TRMs as a potential long term

protection strategy[12,47]. Additionally, vaccine induced TRMs localized to lung tissue of COVID-

19[+] suggest potential beneficial effects in the respiratory tract. Further, IFN-γ secretion by CD8[+]

T cells was predominantly in response to S-peptide in COVID-19[+] and the overall TRM

response to S-peptide was higher in COVID-19[+]. In this context, high frequencies of spike

protein-specific CD4[+]T cell responses have been reported in blood of COVID-19 convalescent

[7,14,15,28,48]. Importantly, CD4[+]T cells are necessary for the formation of protective CD8[+]TRM

during influenza infection; IFN-γ is an essential signal for this process[49]. Consistent with this,

despite the small size in our study, the %TRM within CD4[+] IFN-γ producers was increased in

COVID-19[+] ; a robust 12.5 fold increase in S-peptide responder TRMs was identified within

CD4[+] cells in one COVID-19[+]. Additionally, both IFN-γ[+]CD4[+] and CD8[+] TRM are responding to

both M and N-peptides in addition to S-peptide pools. These data suggest that inclusion of

nucleocapsid as well as other structural viral proteins in vaccine approaches may broaden and

balance the functional profile of memory T cells, resembling control of natural infection.

Additionally, we report for the first time, B cell responses to SARS-CoV-2 peptide pools

against spike protein in COVID-19[+] lung tissues, with a significant change in % S-peptide

responding CD19[+] cells in COVID-19[+] compared to UN lung tissues; it remains to be determined

if the S-peptide responders are tetramer[+] antigen-reactive B cells. The increased immature B

cell frequencies in the COVID-19[+] lungs may represent what is in circulation, as lung tissues

were not perfused prior to *ex vivo* culture. Importantly, we report increased IgA levels and IgA[+]

plasma cells in the lungs of COVID-19[+] compared to UN, either at baseline or in response to

SARS-CoV-2 peptides. The small sample size may prevent us from discerning associations

between vaccination or infection status and/or IgA presence. As secretory IgA plays a crucial

role in protecting mucosal surfaces against respiratory viruses and other pathogens, vaccine

approaches either by nebulization or intranasal delivery may enable enhancement of IgA in the

upper airways and afford long term protection against COVID-19.

 FIGURE LEGENDS

 Figure 1*: Ex Vivo* Perfusion Culture of Human Lung and Exposure to SARS-CoV-2 Peptides. **A**.

 Ex vivo model setup process. **B**. Bioreactor chamber showing ECM volume containing tissue. **C**.

 Peptide exposure protocol.

 Figure 2: Local T Cell Response to SARS-CoV-2 Peptides within Lung Tissue Cores. **A-G.**

 Baseline T cell differences within lung tissue from uninfected individuals (UN) and individuals

 recovering from COVID-19 (COVID-19$^+$). **H-N.** Impact of SARS-CoV-2 peptide exposure on T

 cell populations in UN and COVID-19$^+$ lung tissue. n=8 UN and n=4 COVID-19$^+$. Statistics

 shown in blue are comparisons between control and peptide exposed samples within each

 group (UN and COVID-19$^+$). Statistics shown in black are the change in response between UN

 and COVID-19$^+$ for each peptide when compared to the corresponding control.

 Figure 3: Memory T Cell Response to SARS-CoV-2 Peptides within the Lung. **A-J.** Baseline

 differences in memory T cells within lung tissue from uninfected individuals (UN) and individuals

 recovering from COVID-19 (COVID-19$^+$). **K-T.** Impact of SARS-CoV-2 peptide exposure on

 memory T cell populations in UN and COVID-19$^+$ lung tissue. n=8 UN and n=4 COVID-19$^+$.

 Statistics shown in blue are comparisons between control and peptide exposed samples within

 each group (UN and COVID-19$^+$). Statistics shown in black are the change in response between

 UN and COVID-19$^+$ for each peptide when compared to the corresponding control.

 Figure 4: Local B Cell Response to SARS-CoV-2 Peptides within the Lung. **A-C.** Baseline

 differences in B cell populations within lung tissue from uninfected individuals (UN) and

 individuals recovering from COVID-19 (COVID-19$^+$). **D-F.** Impact of SARS-CoV-2 peptide

 exposure on B cell populations in UN and COVID-19$^+$ lung tissue. **G-H.** Quantification of

 circulating SARS-CoV-2 specific IgA (**G**) and IgG (**H**), opaque symbols indicate positive samples

 (measurements over threshold). **I**. Photomicrographs showing CD138$^+$ plasma cells (red)

 secreting IgA (green) in UN (left) and COVID-19$^+$ samples (right) at day 0 (starting tissue). White

 arrows pointing to CD138$^+$ plasma cells secreting IgA, grey dashed arrows pointing to CD138$^+$

348 plasma cells without IgA secretion. n=4 UN and n=3 COVID-19$^+$. Statistics shown in blue are

349 comparisons between control and peptide stimulated samples within each group (UN and

350 COVID-19$^+$). Statistics shown in black are the change in response between UN and COVID-19$^+$

351 for each peptide when compared to the corresponding controls.

METHODS

Clinical Sample Collection: De-identified, remnant surgical specimen were obtained from lobectomy and wedge resection surgeries performed at the University of Alabama at Birmingham. For peptide exposure studies, 12 tissue specimen were obtained from patients with no history of SARS-CoV-2 infection and 4 tissue specimen were obtained from patients who had previously tested positive for SARS-CoV-2 and cleared the infection. This study was approved by the University of Alabama at Birmingham Institutional Review Board (IRB-300003092 and IRB-300003384) and conducted following approved guidelines and regulations. Written informed consent was obtained from all participants. Patient demographics are described in **Table 1**.

Sample Processing and *Ex Vivo* Perfusion Culture: 5 mm diameter tissue cores were generated from remnant surgical specimen using a tissue coring press (Alabama Research and Development, USA). One tissue core was placed into the central chamber of a polydimethylsiloxane (PDMS, Krayden, USA) bioreactor containing a mixture of extracellular matrix (ECM, 90% collagen type 1 (Advanced Biomatrix, USA) + 10% growth factor reduced Matrigel (Corning, USA)) components for structural support as previously described[50]. The tissue/ECM volume was then penetrated with five 400 micron Teflon coated stainless steel wires to generate through-channels for tissue perfusion. Following ECM polymerization, the wires were removed and the through-channels were filled with tissue culture media (1:1 mixture of X-Vivo15 and Bronchial Epithelial Growth media (Lonza, USA) with antibiotics (MP Biomedicals, USA)). The bioreactor was then connected to a perfusion system, that contained a media reservoir, peroxide cured silicon tubing (Cole Parmer, USA), a collection reservoir and peristaltic pump (ESI, USA), and tissue culture media was perfused through the tissue volume for 5 to 14 days (37°C, 5% CO_2), with media changed every 3 days. At the end of each experiment, a portion of each tissue was fixed separately for histologic processing and collagenase B (Roche, Switzerland) digestion for flow cytometry analysis

SARS-CoV-2 Peptide Exposures: For *in vitro* peptide exposures, on day 5 of culture, conditioned media was collected from the collection reservoir and 0.6 nM SARS-CoV-2 peptides (Peptivator peptide pools: M, N and S, Miltenyi Biotec, USA) or vehicle control (cell culture grade water) were added to the tissue chamber of the bioreactor per manufacturer instructions. Following a four hour static incubation, tissue culture media containing brefeldin A and monensin (BD, Germany) was perfused throughout the tissue chamber for an additional 14 hours.

Multiparametric Flow Cytometry: The following antibodies were used for multiparametric flow cytometry for T cell analysis: Anti-CD3-alexafluor 700 (Clone: UCHT1); anti-CD4-FITC (Clone: RPA-T4); anti-CD69-BV563 (Clone: FN50) from BD Biosciences (Germany). Anti-HLA-DR-APC (Clone: LN3); anti-CD3-PE-Cy7 (Clone: UCHT1); anti-CD8-APC (Clone: 53-6.7); anti-Interferon-γ-Alexafluor700 (Clone:B27) from eBioscience (Thermo Fisher, Germany). Anti-Ki-67-Dylight350 (Clone: 1297A) from Novus (USA). Anti-CD45-APC-Cy7 (Clone:2D1); anti-CCR7-Pacific Blue (Clone: G043H7); anti-CD45RA-BV510 (Clone:HI100); anti-CD45RO-PerCy-Cy5.5 (Clone:UCHL1); anti-CD62L-BV650 (Clone:DREG-56); anti-CD103-PE (Clone:Ber-ACT8): anti-CD8-BV510 (Clone:SK1); anti-CD38-PE-Cy7 (Clone:HB-7); anti-CD154-PE/Dazzle (Clone:24-31) anti-PD-1-BV605 (Clone:NAT105); anti-TNF-αBV605 (Clone:MAb11) from Biolegend (USA). The following antibodies were used for multiparametric flow cytometry for analysis of resident immune and structural cells: Anti-CD64-PerCp-eFluor710 (Clone: 10.1); anti-CD11b-APC-Cy7 (Clone: ICRF44); anti-HLA-DR-FITC (Clone: LN3); anti-EpCAM(CD326)-Alexafluor 594 (Clone:9C4) from eBioscience (Thermo Fisher, Germany). Anti-CD16-PE (Clone: 3G8); anti-CD45-Pacific Blue (Clone: HI30); anti-CD66b-PerCP-Cy5.5 (Clone: G10F5) from Biolegend (USA). Anti-CD31-Alexafluor 700 (Clone: UCHT1) from BD Biosciences (Germany) anti-PanCytokerain-APC (Clone: C-11) and anti-Ki-67-Dylight350 (Clone: 1297A) from Novus Biologicals (USA). The following antibodies were used for multiparametric flow cytometry for B cell analysis: anti-CD10-BV650 (Clone:HI10A); anti-CD19-eFluor450 (Clone:HIB19) from

eBioscience (Thermo Fisher, Germany). Anti-CD45-BV605 (Clone: 2D1); anti-CD21-PerCP-Cy5

(Clone:Bu32); anti-CD24-APC-Cy7 (Clone:ML5); anti-CD27-APC (Clone: M-T271); anti-CD38-

PE-Cy7 (Clone: HB-7); anti-CD138-BV510 (Clone:MI15); anti-IgD-FITC (Clone:IA6-2); anti-IgM-

PE (Clone:MHM-88) from Biolegend (USA). The Foxp3 / Transcription Factor Staining Buffer

Set (Thermo Fisher, Germany) and the Cytofix/Cytoperm Fixation/Permeablization kit (BD,

Germany) were used according to the manufacturer's protocol to stain for intracellular

molecules (intranuclear and cytoplasmic molecules, respectively). Analyses were performed on

FACSymphony A3 Cell Analyzer with FACSDiva software version 8.0.1 (BD Biosciences,

Germany). Data were analyzed with FlowJo 10.7.1 (Treestar, USA).

Analysis of IgA and IgG: Analysis of secreted Sars-CoV-2 specific IgA and IgG was performed

using conditioned media and serum along with ELISA kits (EuroImmun). Conditioned media was

concentrated using Amicon Ultra-4 100 K Centrifugal Filter Units (Millipore Sigma), prior to

analysis. Samples were spun at 4000 x g for 15 minutes using a swinging bucket centrifuge, per

manufacture's recommendation. ELISA assays were performed following the manufacturer's

recommendations (1:101 dilution of serum samples and 1:5 dilution of conditioned media

samples) and a threshold was set to determine positive levels of immunoglobulin based on the

average level of immunoglobulin in control media samples.

Histologic Processing and Analysis: Following *ex vivo* culture, a portion of each cultured

tissue was fixed with neutral buffered formalin, processed to paraffin, and histological (FFPE)

sections were prepared, as previously described[51]. 5 micron sections were stained with

hematoxylin and eosin (H&E) to evaluate tissue morphology and cell density (number of cells

per cross-sectional area) as described before[52].

Immunofluorescence Staining and Analysis: Immunofluorescence staining was performed

on FFPE sections to detect plasma cells secreting IgA. Anti-CD138 (Syndecan-1, 1:50, clone

aa18-218, LSBio) was detected with anti-mouse Alexafluor 647 (1:500 Life Technologies) and

IgA (1:100, clone Mc24-2E11, LSBio) was detected with anti-rabbit Alexafluor-594 (1:500, Life

Technologies), following antigen retrieval (10 mM citrate buffer, pH 6). 4′,6-Diamidino-2-

phenylindole (DAPI) (1:1000) was used as a nuclear counterstain. Sections were imaged using

a Nikon A1R-HD25 confocal microscope with a Plan Apo λ 10x objective (na .5 wd 4000).

Matrix Proteomics: For matrix protein enrichment and extraction, tissue samples were

prepared as described before[53]. Briefly, tissues were processed using the Millipore

Compartment Protein Extraction Kit with some modifications of the described methodology[53]

and all fractions were stored at -80° overnight. The ECM fraction was then reconstituted in 8M

urea and deglycosylated. The urea-insoluble fraction was collected by centrifugation,

reconstituted in 1x LDS sample buffer, and sonicated for 20 minutes in an ultrasonic water bath.

Both urea-soluble and insoluble fractions were quantified via EZQ protein assay, and an equal

amount per sample was loaded onto 10% Bis-tris gels and gels were stained overnight with

Colloidal Coomassie. Each sample was then digested in 3 fractions with trypsin overnight and

high resolution LC-ESI-MS/MS analysis was completed. Data was searched against human

subset of Uniref100 database with Carbamidomethylation, Oxidation, and Hydroxyproline.

Measuring Lactate Dehydrogenase: Lactate dehydrogenase (LDH) was measured in

conditioned media using the Invitrogen CyQUANT LDH Cytotoxicity Assay (Thermo Fisher,

Germany) following manufacturer's instruction.

Statistical Analysis: The measured flow data was summarized by presenting descriptive

statistics, such as mean with standard error of the mean (SEM), in the uninfected and

convalescent groups. Changes of the measurement between control and each of peptides were

computed separately. Two sample t-tests and Wilcoxon rank- sum tests were performed to

determine if means of the changes were different between uninfected and convalescent groups.

Mean and SD of the outcome measured were estimated by control and peptides within

uninfected and convalescent groups respectively. To evaluate difference in the outcome

between control and each of peptides within each of the groups, paired t-test and Wilcoxon

signed-rank tests were used. All other statistical analyses were performed using SAS 9.4 (SAS

Institute, USA). Statistical significance was determined at P-value < 0.05.

ACKNOWLEDGEMENTS

Research reported in this publication was supported by the University of Alabama at

Birmingham School of Medicine COVID-19 pilot grant and P42 ES027723 (Project 2) awarded

to J.S.D., UAB Comprehensive Flow Cytometry Core Facility (NIH P30 AR048311 and NIH P30

AI27667), the UAB Tissue Biorepository, the UAB Pathology Core Research Laboratories and

the UAB High Resolution Imaging Facility. The authors would like to thank Dr. Paul Goepfert for

providing insights in T cell immunology in infection and Dr. Maite Sabalza for expertise in

IgA/IgG ELISA.

AUTHOR CONTRIBUTIONS

K.F.G. was involved in bioreactor model set up, experimental design and execution, data

collection, data analysis, and manuscript and figure preparation. C.S.S., S.A.K., and A.M.W.

were involved in data collection, data analysis, and manuscript editing. Y.W. was involved in

data collection and manuscript editing. J.L.B. was involved in bioreactor design and production

and manuscript editing. J.A.M. was involved in the design and analysis of ECM proteomics and

manuscript editing. Y.K. was completed statistical analyses and was involved in manuscript

editing. V.J.T. and K.S.H were involved in experimental design and reviewing the overall

concepts and thought process of the manuscript. M.A. gave critical insights for the manuscript.

J.M.D. facilitated collection of remnant surgical specimen and was involved in manuscript

editing. J.S.D. was involved in experimental design and oversight, data interpretation, and

manuscript and figure preparation.

Correspondence and requests for materials should be addressed to Jessy Deshane

(jessydeshane@uabmc.edu)

REFERENCES

BioSpace. Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19. (2020). <https://www.biospace.com/article/releases/enzo-announces-issuance-of-u-s-patent-for-methods-of-using-proprietary-compound-sk1-i-in-patients-exploring-options-for-development-as-a-potential-treatment-for-covid-19/>.

Control, C. F. D. United States COVID-19 Cases, Deaths, and Laboratory Testing (NAATs) by State, Territory, and Jurisdiction. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html.>.

Worldometer. COVID-19 Coronavirus Pandemic (2022). <https://www.worldometers.info/coronavirus/#countries>.

De Biasi, S. *et al.* Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nat Commun* **11**, 3434, doi:10.1038/s41467-020-17292-4 (2020).

de Candia, P., Prattichizzo, F., Garavelli, S. & Matarese, G. T Cells: Warriors of SARS-CoV-2 Infection. *Trends Immunol* **42**, 18-30, doi:10.1016/j.it.2020.11.002 (2021).

Files, J. K. *et al.* Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. *J Clin Invest* **131**, doi:10.1172/JCI140491 (2021).

Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **584**, 457-462, doi:10.1038/s41586-020-2550-z (2020).

Toor, S. M., Saleh, R., Sasidharan Nair, V., Taha, R. Z. & Elkord, E. T-cell responses and therapies against SARS-CoV-2 infection. *Immunology* **162**, 30-43, doi:10.1111/imm.13262 (2021).

Farinholt, T. *et al.* Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. *medRxiv*, doi:10.1101/2021.06.28.21258780 (2021).

Olsen, R. J. *et al.* Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. *Am J Pathol*, doi:10.1016/j.ajpath.2021.07.002 (2021).

Zhao, J. *et al.* Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. *Immunity* **44**, 1379-1391, doi:10.1016/j.immuni.2016.05.006 (2016).

Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J Virol* **88**, 11034-11044, doi:10.1128/JVI.01505-14 (2014).

Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol* **84**, 9318-9325, doi:10.1128/JVI.01049-10 (2010).

Grifoni, A. *et al.* Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions. *SSRN*, 3541361, doi:10.2139/ssrn.3541361 (2020).

Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415, doi:10.1016/j.cell.2020.05.015 (2020).

Nelde, A. *et al.* SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol* **22**, 74-85, doi:10.1038/s41590-020-00808-x (2021).

| 527 | 17 | Schulien, I. *et al.* Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. *Nat Med* **27**, 78-85, doi:10.1038/s41591-020-01143-2 (2021). |

17   Schulien, I. *et al.* Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells.
Nat Med **27**, 78-85, doi:10.1038/s41591-020-01143-2 (2021).

18   Kared, H. *et al.* CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from
the entire SARS-CoV-2 proteome and show kinetics of early differentiation. *bioRxiv*,
doi:10.1101/2020.10.08.330688 (2020).

19   Meckiff, B. J. *et al.* Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in
COVID-19. *Cell* **183**, 1340-1353 e1316, doi:10.1016/j.cell.2020.10.001 (2020).

20   Ong, E. Z. *et al.* A Dynamic Immune Response Shapes COVID-19 Progression. *Cell Host Microbe*
27, 879-882 e872, doi:10.1016/j.chom.2020.03.021 (2020).

21   Parveen, F. *et al.* Role of Ceramidases in Sphingolipid Metabolism and Human Diseases. *Cells* **8**,
doi:10.3390/cells8121573 (2019).

22   Rydyznski Moderbacher, C. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute
COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996-1012 e1019,
doi:10.1016/j.cell.2020.09.038 (2020).

23   Sattler, A. *et al.* SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient
predisposition. *J Clin Invest* **130**, 6477-6489, doi:10.1172/JCI140965 (2020).

24   Peng, Y. *et al.* Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK
convalescent individuals following COVID-19. *Nat Immunol* **21**, 1336-1345, doi:10.1038/s41590-
020-0782-6 (2020).

25   Rodda, L. B. *et al.* Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
Cell **184**, 169-183 e117, doi:10.1016/j.cell.2020.11.029 (2021).

26   Jung, J. H. *et al.* SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent
patients for 10 months with successful development of stem cell-like memory T cells. *Nat
Commun* **12**, 4043, doi:10.1038/s41467-021-24377-1 (2021).

27   Lipsitch, M., Grad, Y. H., Sette, A. & Crotty, S. Cross-reactive memory T cells and herd immunity
to SARS-CoV-2. *Nat Rev Immunol* **20**, 709-713, doi:10.1038/s41577-020-00460-4 (2020).

28   Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
Convalescent Individuals. *Immunity* **52**, 971-977 e973, doi:10.1016/j.immuni.2020.04.023
(2020).

29   Tavukcuoglu, E., Horzum, U., Cagkan Inkaya, A., Unal, S. & Esendagli, G. Functional
responsiveness of memory T cells from COVID-19 patients. *Cell Immunol* **365**, 104363,
doi:10.1016/j.cellimm.2021.104363 (2021).

30   Shaan Lakshmanappa, Y. *et al.* SARS-CoV-2 induces robust germinal center CD4 T follicular
helper cell responses in rhesus macaques. *Nat Commun* **12**, 541, doi:10.1038/s41467-020-
20642-x (2021).

31   Grigoryan, L. & Pulendran, B. The immunology of SARS-CoV-2 infections and vaccines. *Semin
Immunol* **50**, 101422, doi:10.1016/j.smim.2020.101422 (2020).

32   Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat Rev
Immunol* **20**, 457-458, doi:10.1038/s41577-020-0389-z (2020).

33   Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644,
doi:10.1038/s41586-021-03207-w (2021).

34   Tre-Hardy, M. *et al.* Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance
in health care workers; a third dose is necessary. *J Infect* **83**, 559-564,
doi:10.1016/j.jinf.2021.08.031 (2021).

35   Tre-Hardy, M., Cupaiolo, R., Wilmet, A., Beukinga, I. & Blairon, L. Waning antibodies in SARS-
CoV-2 naive vaccinees: Results of a three-month interim analysis of ongoing immunogenicity
and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. *J Infect* **83**, 381-412,
doi:10.1016/j.jinf.2021.06.017 (2021).

36 Abbasi, J. SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination. *JAMA* **326**, 901-901,
doi:10.1001/jama.2021.15115 (2021).
37 Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6
Months. *N Engl J Med* **385**, e84, doi:10.1056/NEJMoa2114583 (2021).
38 Sterlin, D., Malaussena, A. & Gorochov, G. [IgA dominates the early neutralizing antibody
response to SARS-CoV-2 virus]. *Med Sci (Paris)* **37**, 968-970, doi:10.1051/medsci/2021154
(2021).
39 Wang, Z. *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med* **13**,
doi:10.1126/scitranslmed.abf1555 (2021).
40 Kusnadi, A. *et al.* Severely ill COVID-19 patients display impaired exhaustion features in SARS-
CoV-2-reactive CD8(+) T cells. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abe4782 (2021).
41 Boppana, S. *et al.* SARS-CoV-2-specific circulating T follicular helper cells correlate with
neutralizing antibodies and increase during early convalescence. *PLoS Pathog* **17**, e1009761,
doi:10.1371/journal.ppat.1009761 (2021).
42 Gong, F. *et al.* Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent
individuals. *J Clin Invest* **130**, 6588-6599, doi:10.1172/JCI141054 (2020).
43 Rha, M. S. *et al.* PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but
Functional in Patients with COVID-19. *Immunity* **54**, 44-52 e43,
doi:10.1016/j.immuni.2020.12.002 (2021).
44 Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.
Nat Med **26**, 842-844, doi:10.1038/s41591-020-0901-9 (2020).
45 Grau-Exposito, J. *et al.* Peripheral and lung resident memory T cell responses against SARS-CoV-
2. *Nat Commun* **12**, 3010, doi:10.1038/s41467-021-23333-3 (2021).
46 Wu, T. *et al.* Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-
protection against pulmonary virus infection. *J Leukoc Biol* **95**, 215-224, doi:10.1189/jlb.0313180
(2014).
47 Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to respiratory
coronaviruses. *Immunol Res* **59**, 118-128, doi:10.1007/s12026-014-8534-z (2014).
48 Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
COVID-19. *Cell* **183**, 158-168 e114, doi:10.1016/j.cell.2020.08.017 (2020).
49 Oja, A. E. *et al.* Trigger-happy resident memory CD4(+) T cells inhabit the human lungs. *Mucosal*
Immunol **11**, 654-667, doi:10.1038/mi.2017.94 (2018).
50 Goliwas, K. F. *et al.* Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a
Tissue Engineered Breast Cancer Model. *Sci Rep* **7**, 14167, doi:10.1038/s41598-017-14326-8
(2017).
51 Goliwas, K. F., Miller, L. M., Marshall, L. E., Berry, J. L. & Frost, A. R. Preparation and Analysis of
In Vitro Three Dimensional Breast Carcinoma Surrogates. *J Vis Exp*, doi:10.3791/54004 (2016).
52 Goliwas, K. F. *et al.* Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an
Engineered Lung Cancer Model. *Front Oncol* **11**, 654922, doi:10.3389/fonc.2021.654922 (2021).
53 Naba, A., Clauser, K. R. & Hynes, R. O. Enrichment of Extracellular Matrix Proteins from Tissues
and Digestion into Peptides for Mass Spectrometry Analysis. *J Vis Exp*, e53057,
doi:10.3791/53057 (2015).

Figure 1

a

Remnant surgical specimen → 5 mm tissue cores generated → Tissue placed in bioreactor chamber containing ECM and penetrated with wires

8 mm
10 mm
6 mm

Wires removed following ECM polymerization and media added

b

Bioreactor connected to perfusion loop and peristaltic pump

c Starting Tissue (Day 0):

UN (n=8)   COVID19+ (n=4)

OR

4-5 days perfusion culture

Peptide Addition
0.6 nM (4 hours static incubation)

18 hours perfusion culture

Tissue dissociation & cell phenotyping

Figure 2

Figure 3

Figure 4